Associations of obesity, abdominal neoplasms and comorbidities DOI Creative Commons

I.O. Malyshevskyi,

В. Т. Степан, A G Iftodiĭ

и другие.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), Год журнала: 2025, Номер 21(1), С. 11 - 16

Опубликована: Фев. 23, 2025

Background. Multiple recent studies suggest that at least 5–10 % of all malignancies are attributed to metabolic disorders and obesity. Excessive weight may also significantly influence outcomes aggravate treatment-related adverse effects patients’ follow-up. The purpose the study was clarify clinical pathogenetic significance excessive body comorbidities in patients with abdominal malignant neoplasms. Materials methods. This cohort-based observational research involves a total 952 (mean age 62.35 ± 11.57 years) divided into (23.95 %, mass index ≥ 26 kg/m2) control (76.05 ≤ 25 groups. diagnosis, staging, prevalence process, concomitant pathology, several anthropometric statistical parameters were determined, treatment (duration postoperative period, incidence complications) assessed. Results. No significant differences staging identified between Relative fat higher group compared controls — 33.56 1.01 vs. 27.01 2.25 p = 0.009. Edmonton Obesity Staging System showed stages for as well. mean Charlson comorbidity (p 0.005), especially male population. factor influencing complications 0.66 (95% confidence interval (CI) 0.51–0.78), sensitivity 0.88 CI 0.71–0.96), specificity 0.65 0.39–0.85). Conclusions. is aggravating condition malignancies, increasing risk by 1.29–6.96 times.

Язык: Английский

Associations of obesity, abdominal neoplasms and comorbidities DOI Creative Commons

I.O. Malyshevskyi,

В. Т. Степан, A G Iftodiĭ

и другие.

INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), Год журнала: 2025, Номер 21(1), С. 11 - 16

Опубликована: Фев. 23, 2025

Background. Multiple recent studies suggest that at least 5–10 % of all malignancies are attributed to metabolic disorders and obesity. Excessive weight may also significantly influence outcomes aggravate treatment-related adverse effects patients’ follow-up. The purpose the study was clarify clinical pathogenetic significance excessive body comorbidities in patients with abdominal malignant neoplasms. Materials methods. This cohort-based observational research involves a total 952 (mean age 62.35 ± 11.57 years) divided into (23.95 %, mass index ≥ 26 kg/m2) control (76.05 ≤ 25 groups. diagnosis, staging, prevalence process, concomitant pathology, several anthropometric statistical parameters were determined, treatment (duration postoperative period, incidence complications) assessed. Results. No significant differences staging identified between Relative fat higher group compared controls — 33.56 1.01 vs. 27.01 2.25 p = 0.009. Edmonton Obesity Staging System showed stages for as well. mean Charlson comorbidity (p 0.005), especially male population. factor influencing complications 0.66 (95% confidence interval (CI) 0.51–0.78), sensitivity 0.88 CI 0.71–0.96), specificity 0.65 0.39–0.85). Conclusions. is aggravating condition malignancies, increasing risk by 1.29–6.96 times.

Язык: Английский

Процитировано

0